Clinical trial · Interventional
Sentinel Node After Neoadjuvancy In Node-Positive Breast Cancer
Sentinel Node After Neoadjuvancy In Node-Positive Breast Cancer: SANA Multicentric Study
NCT04865549CI-TRIAL-00051537SANAcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The status of the axillary lymph nodes is one of the main prognostic factors in breast cancer (BC). SLNB is currently the standard staging method for patients with clinically node-negative (cN0) breast cancer. In patients with a positive SLN and in those with affected lymph nodes at the beginning (cN+), LND is the standard of treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SNB + TAD + Lymphadenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TAD arm
- description
- Sentinel Node Biopsy + Targetted Axillary Dissection (Clipped cN1 node) extraction + lymphadenectomy.
- interventionNames
- Procedure: SNB + TAD + Lymphadenectomy
Primary outcomes (1)
- measure
- Targetted axilary dissection detection rate in cN+ after neoadjuvant therapy
- timeFrame
- immediately after surgery
- description
- Targetted axilary dissection detection rate in cN+ after neoadjuvant therapy (Sentinel lymph node plus cliped node)
Secondary outcomes (7)
- measure
- False negative Rate
- timeFrame
- immediately after surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age equal to or greater than 18 years * Patients with a diagnosis of T1-T3 primary infiltrating breast carcinoma * Axillary clinical involvement (cN +) * Confirmation by FNAC or BAG of lymph node involvement * Candidates for neoadjuvant chemotherapy including anthracyclines and taxanes Exclusion Criteria: * T4 tumors * Supra / infraclavicular lymph node or internal mammary chain (cN3) involvement * Previous ipsilateral breast or axillary surgery * Distant metastasis at diagnosis (M1)
References
Publications (0)
Data not yet available
No reference posted for this study.